Poly (l‐glutamic acid)‐g‐methoxy poly (ethylene glycol)‐gemcitabine conjugate improves the anticancer efficacy of gemcitabine

[1]  V. Préat,et al.  Injectable nanomedicine hydrogel for local chemotherapy of glioblastoma after surgical resection , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[2]  Kui Luo,et al.  Enzyme-responsive peptide dendrimer-gemcitabine conjugate as a controlled-release drug delivery vehicle with enhanced antitumor efficacy. , 2017, Acta biomaterialia.

[3]  Xuesi Chen,et al.  A poly(l-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor. , 2017, Acta biomaterialia.

[4]  K. Olive,et al.  Current and Emerging Therapies in Metastatic Pancreatic Cancer , 2017, Clinical Cancer Research.

[5]  N. R. Jagannathan,et al.  Multi-functional nanoparticles as theranostic agents for the treatment & imaging of pancreatic cancer. , 2017, Acta biomaterialia.

[6]  Xuefei Zhang,et al.  Patupilone-loaded poly(L-glutamic acid)-graft-methoxy-poly(ethylene glycol) micelle for oncotherapy , 2017, Journal of biomaterials science. Polymer edition.

[7]  R. Hill,et al.  CANCER-ASSOCIATED FIBROBLAST EXOSOMES REGULATE SURVIVAL AND PROLIFERATION OF PANCREATIC CANCER CELLS , 2016, Oncogene.

[8]  A. Molven,et al.  A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[9]  V. Ellenrieder,et al.  Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon? , 2016, Gut.

[10]  F. Hirsch,et al.  New and emerging targeted treatments in advanced non-small-cell lung cancer , 2016, The Lancet.

[11]  Chaoliang He,et al.  Combining disulfiram and poly(l-glutamic acid)-cisplatin conjugates for combating cisplatin resistance. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[12]  A. Nel,et al.  Correction to Use of a Lipid-Coated Mesoporous Silica Nanoparticle Platform for Synergistic Gemcitabine and Paclitaxel Delivery to Human Pancreatic Cancer in Mice , 2016, ACS nano.

[13]  J. Zink,et al.  Protein-gold clusters-capped mesoporous silica nanoparticles for high drug loading, autonomous gemcitabine/doxorubicin co-delivery, and in-vivo tumor imaging. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[14]  Xuesi Chen,et al.  Solid Tumor Therapy Using a Cannon and Pawn Combination Strategy , 2016, Theranostics.

[15]  D. Kohane,et al.  Self-assembled gemcitabine-gadolinium nanoparticles for magnetic resonance imaging and cancer therapy. , 2016, Acta biomaterialia.

[16]  V. Préat,et al.  Lauroyl-gemcitabine-loaded lipid nanocapsule hydrogel for the treatment of glioblastoma. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[17]  Huan Meng,et al.  Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer. , 2016, ACS nano.

[18]  R. Holcombe,et al.  Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer , 2016, Clinical Cancer Research.

[19]  J. Ji,et al.  Theranostic reduction-sensitive gemcitabine prodrug micelles for near-infrared imaging and pancreatic cancer therapy. , 2016, Nanoscale.

[20]  Xuesi Chen,et al.  A cooperative polymeric platform for tumor-targeted drug delivery , 2015, Chemical science.

[21]  Xuesi Chen,et al.  Cisplatin Loaded Poly(L-glutamic acid)-g-Methoxy Poly(ethylene glycol) Complex Nanoparticles for Potential Cancer Therapy: Preparation, In Vitro and In Vivo Evaluation. , 2016, Journal of biomedical nanotechnology.

[22]  T. Takayama,et al.  A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer , 2015, Cancer Chemotherapy and Pharmacology.

[23]  M. Hidalgo,et al.  Pancreatic cancer: from state-of-the-art treatments to promising novel therapies , 2015, Nature Reviews Clinical Oncology.

[24]  Xuesi Chen,et al.  Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[25]  Xuesi Chen,et al.  Cisplatin-loaded polymeric nanoparticles: characterization and potential exploitation for the treatment of non-small cell lung carcinoma. , 2015, Acta biomaterialia.

[26]  Xuesi Chen,et al.  Cisplatin-loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) nanoparticles as a potential chemotherapeutic agent against osteosarcoma , 2015, Chinese Journal of Polymer Science.

[27]  Meiying Wang,et al.  Use of a Lipid-Coated Mesoporous Silica Nanoparticle Platform for Synergistic Gemcitabine and Paclitaxel Delivery to Human Pancreatic Cancer in Mice , 2015, ACS nano.

[28]  M. Donadelli,et al.  Onconase induces autophagy sensitizing pancreatic cancer cells to gemcitabine and activates Akt/mTOR pathway in a ROS-dependent manner. , 2015, Biochimica et biophysica acta.

[29]  Lily Yang,et al.  Theranostic Nanoparticles Carrying Doxorubicin Attenuate Targeting Ligand Specific Antibody Responses Following Systemic Delivery , 2015, Theranostics.

[30]  N. Chung,et al.  Berberine induces apoptosis via ROS generation in PANC-1 and MIA-PaCa2 pancreatic cell lines , 2014, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[31]  L. Kiew,et al.  Efficacy of a Poly‐L‐Glutamic Acid‐Gemcitabine Conjugate in Tumor‐Bearing Mice , 2012 .

[32]  P. Couvreur,et al.  Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[33]  M. Vandana,et al.  Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer. , 2010, Biomaterials.

[34]  L. Kiew,et al.  Improved plasma stability and sustained release profile of gemcitabine via polypeptide conjugation. , 2010, International journal of pharmaceutics.

[35]  P. Couvreur,et al.  Squalene: A natural triterpene for use in disease management and therapy. , 2009, Advanced drug delivery reviews.

[36]  A. Paci,et al.  Squalenoylation Favorably Modifies the in Vivo Pharmacokinetics and Biodistribution of Gemcitabine in Mice , 2008, Drug Metabolism and Disposition.

[37]  F. Veronese,et al.  Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[38]  L. Cattel,et al.  Characterization of lipophilic gemcitabine prodrug-liposomal membrane interaction by differential scanning calorimetry. , 2006, Molecular pharmaceutics.

[39]  R. Dedrick,et al.  Physiological pharmacokinetic parameters for cis-dichlorodiammineplatinum(II) (DDP) in the mouse , 1992, Journal of Pharmacokinetics and Biopharmaceutics.

[40]  J. Reid,et al.  Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. Brandl,et al.  Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels , 2002, Cancer Chemotherapy and Pharmacology.

[42]  Volker Heinemann,et al.  Gemcitabine: Progress in the Treatment of Pancreatic Cancer , 2000, Oncology.

[43]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[44]  J. Laliberté,et al.  Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. , 1993, Biochemical pharmacology.

[45]  S. Mineishi,et al.  A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.